12 March 2018- Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services from the polypeptide design up to delivery of small quantity of polymer and PMC Isochem will use GMP production facility for clinical batch and commercial supply. In addition, PMC Isochem develops and supplies the strategic high quality Aminoacid N-CarboxyAnhydride raw materials.”This collaboration with Polypeptide Therapeutic Solutions is an important strategic move for PMC Isochem as it opens a new area of development in the pharmaceutical and cosmetic market. It also represents a move forward in the value chain starting from our unique offer of Aminoacid N-CarboxyAnhydride” commented Dr Raj Chakrabarti, ExecutiveVice President of PMC Group International.“This collaboration starts from a solid ground of 3 years of experience demonstrating the global value and synergies resulting from this alliance” says Dr. Yves Robin R&D Director at PMC Isochem “It represents a unique one stop shop offer from the strategic monomer to polypeptide building and from research to GMP production”
“We have developed with PMC ISOCHEM a team that is able to deliver value added solutions, putting together a unique team with knowledge and technology that enables our customers to accelerate time-to-market” says Jose Vicente Pons, Chief Executive Officer at PTS.“The synergies developed between our companies during the last years becomes now a solid strategic movement towards a global solution in polypeptide-based materials” commented Vicent J. Nebot, Chief Technical Officer at PTS “this collaboration represents a unique offer for a growing field, providing to our partners a solid translation from early development to the market”.
About Polypeptide Therapeutic Solutions
PTS is a company devoted to the design and manufacture of polypeptide-based materials for drug delivery and high-tech applications. With more than 20 years of experience in polypeptide & materials science, drug delivery, biological testing, custom manufacturing, quality control and assurance we are committed to one purpose, your success. Proprietary know-how & patent portfolio to provide a 360º solution from early research, through scale-up to first preclinical batches, analytical development & validation within a GLP certified laboratory. We have established an interdisciplinary team with strong skills and a network structure to allow your developments to progress throughout the different stages. Our offer brings a solution in the polypeptide-based technology markets, covering an unmet need towards affordable and compliant polypeptide development and manufacturing.
About PMC Isochem
PMC Isochem provides product/process development, regulatory approvals, pilot scale and
full plant-scale production of drug intermediates and active pharma ingredients (APIs) for major
pharmaceutical companies worldwide to serve the needs of Oncology, Cardiovascular,
Infectious, Gastro-Intestinal, Neurology and rare diseases. PMC Isochem facilities combine
footprint of over 40 acres are located at three sites — Gennevilliers, Pithiviers, and Vert-Le-
Petit — within a 60 miles radius of Paris. The facilities, which are all cGMP US-FDA audited
plants for manufacturing pharmaceutical products. PMC Isochem with 230+ employees
operates as a wholly owned subsidiary of PMC Group France.
PMC Group is a growth oriented, diversified, global chemicals and plastics company dedicated
to innovative solutions to everyday needs in a broad range of end markets including plastics,
consumer products, electronics, paint, packaging, personal care, food, automotive and
pharmaceuticals. The Company was built on a sustainable model of growth through innovation
while promoting social good. PMC operates from a global manufacturing, innovation and
marketing platform with facilities in the Americas, Europe and Asia. More information about
PMC and its activities around the world can be found at www.pmc-group.com.